# reload+after+2024-01-21 06:48:03.711673
address1§180 North LaSalle Street
address2§Suite 1600
city§Chicago
state§IL
zip§60601
country§United States
phone§844 445 5704
website§https://www.xerispharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
fullTimeEmployees§355
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Paul R. Edick', 'age': 67, 'title': 'Chairman & CEO', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 1119599, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John P. Shannon', 'age': 61, 'title': 'President & COO', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 827718, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Beth P. Hecht J.D.', 'age': 59, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 638311, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven M. Pieper', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Allison  Wey', 'title': 'Senior Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kenneth E. Johnson Pharm. D., Pharm.D.', 'age': 60, 'title': 'Senior VP of Global Development & Medical Affairs', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin  McCulloch', 'title': 'Chief Commercial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§9
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.111
priceToSalesTrailing12Months§2.2166154
currency§USD
dateShortInterest§1702598400
forwardEps§-0.29
exchange§NMS
quoteType§EQUITY
shortName§Xeris Biopharma Holdings, Inc.
longName§Xeris Biopharma Holdings, Inc.
firstTradeDateEpochUtc§1529587800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8f5f7125-cc84-3c21-a68b-9d3090e24887
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.5
targetLowPrice§4.0
targetMeanPrice§4.6
targetMedianPrice§4.5
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§1.286
grossMargins§0.82075
ebitdaMargins§-0.18595
trailingPegRatio§None
